Droperidol Infusion for Antiemesis: Safety Concerns and Recommendations

Introduction to Droperidol Safety

• The FDA has added a black box warning to droperidol due to concerns about QT prolongation, risk of torsades de pointes, and potential for sudden cardiac death, particularly in patients with prolonged QTc interval or risk factors for QT prolongation 1, 2, 3, 4, 5

Safety Concerns and Contraindications

• Droperidol is contraindicated in patients with prolonged QTc interval (>440 ms in males, >450 ms in females) or risk factors for QT prolongation including history of congestive heart failure, bradycardia, diuretic use, cardiac hypertrophy, hypokalemia, hypomagnesemia, age ≥65 years, and alcohol abuse 1, 3

Alternative Antiemetics and Administration

• The American Gastroenterological Association recommends considering alternative antiemetics such as 5-HT3 antagonists (ondansetron, granisetron), metoclopramide, and prochlorperazine 1
• Droperidol should be used only when first-line antiemetics are unsuccessful and administered as intermittent boluses rather than continuous infusion, with onset of action of 3-10 minutes and duration of effect of 2-4 hours 1, 3